Fluorescence study for selecting specific ligands toward HER2 receptor: An example of receptor fragment approach
CNR Ibb | back to homepage
CNR Ibb | back to homepage

Fluorescence study for selecting specific ligands toward HER2 receptor: An example of receptor fragment approach (695 views)

Calce E, Monfregola L, Sandomenico A, Saviano M, De Luca S

Eur J Med Chem (ISSN: 0223-5234, 1768-3254, 1768-3254electronic), 2013 Mar; 61: 116-121.

Export to BibTeX    Export to EndNote

Paper type: Journal Article

Impact factor: 3.432, 5-year impact factor: 4.071

Url: http://www.scopus.com/inward/record.url?eid=2-s2.0-84874934514&partnerID=40&md5=2a345ef714f77a95323ded4be2a91e0d

Keywords: Fluorescence Study, Her2 Receptor, Receptor Fragment Model, Selective Ligands, Epidermal Growth Factor Receptor 2, Trastuzumab, Article, Cancer Therapy, Controlled Study, Dissociation, Drug Delivery System, Fluorescence Analysis, Human, Titrimetry, Antibodies, Monoclonal, Humanized, Crystallography, X-Ray, Dose-Response Relationship, Enzyme Inhibitors, Molecular, Molecular Structure, Peptides, Erbb-2, Spectrometry, Structure-Activity Relationship

Affiliations:
*** IBB - CNR ***

Institute of Biostructures and Bioimages, National Research Council, Via Mezzocannone 16, 80138 Naples, Italy
Department of Chemistry and Biochemistry, University of Colorado, Boulder, 80309 CO, United States
Institute of Crystallography, CNR, 70126 Bari, Italy


References:
Not available.
Fluorescence study for selecting specific ligands toward HER2 receptor: An example of receptor fragment approach

Fluorescence titrations allowed us to study the interaction process between Herceptin (Fab)-derived peptides and a synthetic peptide mimicking a subdomain IV of the receptor HER2 (HER2-DIVMP). For some of the investigated peptide/HER2-DIVMP complexes a nanomolar dissociation constant was found. The performed interaction studies were completely immune from interferences of other receptor domains not covered by the design, thus decreasing the possibilities of selecting potential ligands able to bind other subtypes of HER2 receptor family. Our results demonstrate that the adopted receptor fragment approach represents an efficient methodology for selecting new molecules as lead structures specific for the receptor target. For these reasons the optimized compounds could be employed as delivery agents for the receptor-mediated anticancer therapy. (C) 2012 Elsevier Masson SAS. All rights reserved.
Fluorescence study for selecting specific ligands toward HER2 receptor: An example of receptor fragment approach

▼    Carbonic Anhydrase family as target for rational drug design
▼    Galectins: Structure, function and therapeutic potential inhibitors
▼    Chemical modification of natural molecules, such as peptides and polysaccharides, to be employed as therapeutic agents as well as sensor diagnostic tools
▼    Development of integrin subtypes selective ligands: from a first rationally designed peptide to a wide range of molecules
Fluorescence study for selecting specific ligands toward HER2 receptor: An example of receptor fragment approach

Filter those results▼
Query:  [X]
Options:
   Extended  
   IBB affiliation
 
Authors:  [X]
Paper type:  [X]
Start date:  [X]
End date:  [X]
Site:
[Clear form]
Select the year: 
Other filter: ([btitle,keywords] "Fluorescence Study" ...

Sort by:   date ▼▲   title ▲ ▼   journal ▲ ▼   authors ▲ ▼   I.F. ▲ ▼
De Luca S, Verdoliva V, Saviano M
* Peptide Ligands Specifically Targeting HER2 Receptor and the Role Played by a Synthetic Model System of the Receptor Extracellular Domain: Hypothesized Future Perspectives (366 views)
J Med Chem (ISSN: 0022-2623linking, 0022-2623print, 1520-4804), 2020 Dec 24; 63(24): 15333-15343.
Impact Factor: 6.205
View    Export to BibTeX    Export to EndNote

De Luca S, Verdoliva V, Saviano M, Fattorusso R, Diana D
* SPR and NMR characterization of the molecular interaction between A9 peptide and a model system of HER2 receptor: A fragment approach for selecting peptide structures specific for their target (437 views)
J Pept Sci (ISSN: 1075-2617linking, 1099-1387electronic), 2020 Feb; 26(2): e3231-e3231.
Impact Factor: 1.877
View    Export to BibTeX    Export to EndNote

Langella E, Calce E, Saviano M, De Luca S
* Structural identification of an HER2 receptor model binding pocket to optimize lead compounds: a combined experimental and computational approach (585 views)
Mol Biosyst (ISSN: 1742-206x), 2016 Jun 21; 12(7): 2159-2167.
Impact Factor: 2.781
View    Export to BibTeX    Export to EndNote

Calce E, Saviano M, De Luca S
Development of Targeting Ligands for HER2 Receptor: Simplified Receptor Model Employed for Selecting Highly Specific Molecules (501 views)
International Journal Of Peptide Research And Therapeutics, 2016; 22(2): 237-242.
Impact Factor: 0.99
View    Export to BibTeX    Export to EndNote

Calce E, Monfregola L, Saviano M, De Luca S
* HER2-mediated anticancer drug delivery: strategies to prepare targeting ligands highly specific for the receptor (1143 views)
Curr Med Chem (ISSN: 0929-8673, 1875-533x, 1875-533xelectronic), 2015 May 20; 22(21): 2525-2538.
Impact Factor: 3.455
View    Export to BibTeX    Export to EndNote

Calce E, Sandomenico A, Saviano M, Ruvo M, De Luca S
* Cysteine Co-Oxidation Process Driven By Native Peptide Folding: An Example On Her2 Receptor Model System (1039 views)
Amino Acids (ISSN: 0939-4451, 1438-2199, 1438-2199electronic), 2014; 46(5): 1197-1206.
Impact Factor: 3.293
View    Export to BibTeX    Export to EndNote

Avitabile C, Moggio L, Malgieri G, Capasso D, Di Gaetano S, Saviano M, Pedone C, Romanelli A
* Gamma Sulphate Pna (pna S): Highly Selective Dna Binding Molecule Showing Promising Antigene Activity (851 views)
Plosone (ISSN: 1932-6203, 1932-6203electronic, 1932-6203linking), 2012 May 7; 7(5): e35774-e35774.
Impact Factor: 3.73
View    Export to BibTeX    Export to EndNote

Folgiero V, Di Carlo SE, Bossi G, Spugnini E, Di Benedetto A, Bon G, Milella M, Fabi A, Accardo A, Morelli G, Mottolese M, Falcioni R
* Inhibition of p85, the non-catalytic subunit of phosphatidylinositol 3-kinase, exerts potent antitumor activity in human breast cancer cells (919 views)
Cell Death & (ISSN: 2041-4889, 2041-4889electronic), 2012; 3(12): N/D-N/D.
Impact Factor: 6.044
View    Export to BibTeX    Export to EndNote

Troise F, Monti M, Merlino A, Cozzolino F, Fedele C, Russo Krauss I, Sica F, Pucci P, D'Alessio G, De Lorenzo C
* A novel ErbB2 epitope targeted by human antitumor immunoagents (781 views)
Febs Journal (ISSN: 1742-464x), 2011 Apr; 278(7): 1156-1166.
Impact Factor: 3.79
View    Export to BibTeX    Export to EndNote

Monfregola L, Vitale RM, Amodeo P, De Luca S
A SPR strategy for high-throughput ligand screenings based on synthetic peptides mimicking a selected subdomain of the target protein: A proof of concept on HER2 receptor (778 views)
Bioorg Med Chem (ISSN: 0968-0896, 1464-3391, 1464-3391electronic), 2009 Oct 1; 17(19): 7015-7020.
Impact Factor: 2.822
View    Export to BibTeX    Export to EndNote

Insabato L, Amelio I, Quarto M, Zannetti A, Tolino F, De Mauro G, Cerchia L, Riccio P, Baumhoer D, Condorelli G, Terracciano L, De Franciscis V
* Elevated Expression of the Tyrosine Phosphatase SHP-1 Defines a Subset of High-Grade Breast Tumors (810 views)
Oncology (ISSN: 0030-2414), 2009; 77(6): 378-384.
Impact Factor: 2.112
View    Export to BibTeX    Export to EndNote

De Luca S, Sanseverino M, Zocchi I, Pedone C, Morelli G, Ragone R
* Receptor fragment approach to the binding between CCK8 peptide and cholecystokinin receptors: A fluorescence study on type B receptor fragment CCKB-R (352-379) (732 views)
Biopolymers (ISSN: 0006-3525, 0006-6352, 0006-3525print), 2005 Mar; 77(4): 205-211.
Impact Factor: 2.545
View    Export to BibTeX    Export to EndNote

12 Records (10 excluding Abstracts).
Total impact factor: 39.644 (29.87 excluding Abstracts).
Total 5 year impact factor: 38.676 (28.388 excluding Abstracts).

Last modified by Marco Comerci on Tuesday 09 April 2024, 12:56:58
695 views. Last view on Sunday 23 March 2025, 3:03:46